CARSGEN-B(02171),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02171 CARSGEN-B

Market Closed 03-13 16:08:20

15.460

-0.440

-2.77%

High16.340	Low15.030	Vol6.16M
Open16.340	D1 Closing15.900	Amplitude8.24%
Mkt Cap8.81B	Tradable Cap8.81B	Total Shares570.00M
T/O96.27M	T/O Rate1.08%	Tradable Shares570.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02171","market":"HK","secType":"STK","nameCN":"CARSGEN-B","latestPrice":15.46,"timestamp":1773389300004,"preClose":15.9,"halted":0,"volume":6156000,"delay":0,"changeRate":-0.027672955974842737,"floatShares":570000000,"shares":570000000,"eps":-0.20102745603608263,"marketStatus":"Market Closed","change":-0.44,"latestTime":"03-13 16:08:20","open":16.34,"high":16.34,"low":15.03,"amount":96268426,"amplitude":0.08239,"askPrice":15.48,"askSize":19000,"bidPrice":15.46,"bidSize":68500,"shortable":3,"etf":0,"ttmEps":-0.20102745603608263,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1773624600000},"marketStatusCode":7,"adr":0,"listingDate":1623945600000,"exchange":"SEHK","adjPreClose":15.9,"openAndCloseTimeList":[[1773365400000,1773374400000],[1773378000000,1773388800000]],"volumeRatio":0.3757347977378123,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02171","defaultTab":"news","newsList":[{"id":"2618920784","title":"CARsgen Therapeutics Holdings SEHK 2171 Valuation After Stronger 2025 Results And Narrowed Net Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2618920784","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618920784?lang=en_us&edition=fundamental","pubTime":"2026-03-12 00:35","pubTimestamp":1773246927,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics Holdings (SEHK:2171) has drawn attention after reporting full year 2025 earnings, with sales of CNY 125.66 million, a net loss of CNY 97.86 million, and basic loss per share of CNY 0.18.\nSee our latest analysis for CARsgen Therapeutics Holdings.\nThe earnings update appears to have coincided with a sharp shift in sentiment, with a 42.97% 7 day share price return and a 17.85% 30 day share price return at HK$16.37. Meanwhile, the 1 year total shareholder return of 14.16% and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/carsgen-therapeutics-holdings-sehk-2171-valuation-after-stro","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/carsgen-therapeutics-holdings-sehk-2171-valuation-after-stro","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1585","BK4007","BK4539","BK1161","LENZ","02171","BK4139","BK1574","BK1587"],"gpt_icon":0},{"id":"1106814148","title":"Stock Track | CARSGEN-B Soars 11.71% Intraday on Robust Annual Results and Stock Connect Inclusion","url":"https://stock-news.laohu8.com/highlight/detail?id=1106814148","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106814148?lang=en_us&edition=fundamental","pubTime":"2026-03-10 10:31","pubTimestamp":1773109870,"startTime":"0","endTime":"0","summary":"CARSGEN-B (02171) surged 11.71% during intraday trading on Tuesday, extending recent gains for the biotechnology company.The sharp rise follows the company's release of strong annual results, which...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02171"],"gpt_icon":0},{"id":"1118317633","title":"CARSGEN-B Shares Surge Over 12% Following Strong Annual Revenue Growth and Inclusion in Stock Connect","url":"https://stock-news.laohu8.com/highlight/detail?id=1118317633","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118317633?lang=en_us&edition=fundamental","pubTime":"2026-03-10 10:24","pubTimestamp":1773109461,"startTime":"0","endTime":"0","summary":"CARSGEN-B (02171) rose more than 12%, extending its recent gains. At the time of writing, the stock was up 10.78% to HK$15.42, with a turnover of HK$127 million. The company recently released its...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171","BK4585","BK1585","BK1587","BK4588","BK1161","BK1574","VXUS"],"gpt_icon":0},{"id":"2618244696","title":"CARsgen Therapeutics grants 4.27 million share options under post-IPO scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2618244696","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618244696?lang=en_us&edition=fundamental","pubTime":"2026-03-09 22:08","pubTimestamp":1773065332,"startTime":"0","endTime":"0","summary":"CARsgen granted 4.27 million share options to 181 grantees under its post-IPO share option scheme. The options have an exercise price of HKD 13.92 per share and require HKD 1 consideration per grantee upon acceptance. Separately, CARsgen granted 3.31 million restricted share units to 178 grantees under its 2019 equity incentive plan. The RSUs have nil consideration and nil purchase price. Both the options and RSUs vest 25% annually from March 9, 2027 through March 9, 2030.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 09, 2026, and is solely resp","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDL4bd0tF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1585","BK1161","02171","BK1587"],"gpt_icon":0},{"id":"2618616952","title":"BUZZ-CARsgen Therapeutics jumps most on record as full-year losses narrow","url":"https://stock-news.laohu8.com/highlight/detail?id=2618616952","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618616952?lang=en_us&edition=fundamental","pubTime":"2026-03-09 11:20","pubTimestamp":1773026430,"startTime":"0","endTime":"0","summary":"BUZZ-CARsgen Therapeutics jumps most on record as full-year losses narrow** Shares of CARsgen Therapeutics Holdings 2171.HK jump as much as 42.6% to HK$15.50, their biggest intraday pct gain since debut in June 2021 ** Stock hits its highest level since February 26** The Chinese cell therapies developer says its 2025 net loss narrowed to 103 million yuan , from 798 million yuan loss in 2024, due to decrease in research and development, and administrative expenses, among others** YTD, stock down 7.6%, Hang Seng Biotech Index .HSBIO down 1.8%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL1N3ZX03H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","BK1585","02171","BK1587"],"gpt_icon":0},{"id":"1114135542","title":"CARSGEN-B Surges Over 32% Following Earnings Release, Annual Loss Narrows by 87.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1114135542","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114135542?lang=en_us&edition=fundamental","pubTime":"2026-03-09 09:51","pubTimestamp":1773021104,"startTime":"0","endTime":"0","summary":"CARSGEN-B (02171) saw its share price jump more than 32% after announcing its financial results. As of the latest update, the stock had risen by 32.48%, trading at HK$14.40 with a turnover of...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1585","BK1574","02171","BK1587"],"gpt_icon":0},{"id":"2618690704","title":"CARsgen Therapeutics Shares to Join Stock Connect Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2618690704","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618690704?lang=en_us&edition=fundamental","pubTime":"2026-03-09 09:33","pubTimestamp":1773020011,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics (HKG:2171) said its shares were eligible for inclusion in the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect programs, according to a Hong Kong bourse filing Monday.The inclusions are effective March 9.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4539","BK4007","BK1587","02171","LENZ","BK1161","BK1574","BK1585"],"gpt_icon":0},{"id":"1162431359","title":"Stock Track | CARSGEN-B Soars 15.00% Intraday on Inclusion in Stock Connect Southbound Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1162431359","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162431359?lang=en_us&edition=fundamental","pubTime":"2026-03-09 09:31","pubTimestamp":1773019900,"startTime":"0","endTime":"0","summary":"CARSGEN-B (02171) saw its stock price soar 15.00% during intraday trading on Monday, following the company's announcement that its shares have been added to the southbound eligible list of the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02171"],"gpt_icon":0},{"id":"1168644813","title":"CARSGEN-B (02171) Added to Southbound Stock Connect Eligibility List","url":"https://stock-news.laohu8.com/highlight/detail?id=1168644813","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168644813?lang=en_us&edition=fundamental","pubTime":"2026-03-09 08:24","pubTimestamp":1773015859,"startTime":"0","endTime":"0","summary":"CARSGEN-B (02171) announced that, according to the \"Notice on Adjustments to Southbound Securities under the Shanghai-Hong Kong Stock Connect\" and the \"Announcement on Adjustments to the List of...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VT","BK1587","161027","BK4588","02171","VXUS","BK1161","BK1585","BK1574","BK4585"],"gpt_icon":0},{"id":"1130305862","title":"CARSGEN-B (02171) Announces Inclusion in Southbound Stock Connect","url":"https://stock-news.laohu8.com/highlight/detail?id=1130305862","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130305862?lang=en_us&edition=fundamental","pubTime":"2026-03-09 08:02","pubTimestamp":1773014579,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics Holdings Limited (CARSGEN-B, 02171) disclosed its inclusion in the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect, effective March 9, 2026. According...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"gpt_icon":0},{"id":"2618569263","title":"CARsgen Therapeutics added to Stock Connect southbound eligible list effective March 9, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618569263","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618569263?lang=en_us&edition=fundamental","pubTime":"2026-03-09 08:01","pubTimestamp":1773014496,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics Holdings Ltd.  said its Hong Kong-listed shares have been added to the list of eligible stocks for southbound trading via the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs, effective March 9, 2026. The company said the move will allow eligible mainland Chinese investors to buy its shares through Stock Connect and is expected to improve market attention and liquidity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 09, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDL7QYM0b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171","BK1161","BK1587","BK1574","BK1585"],"gpt_icon":0},{"id":"2617638376","title":"BRIEF-Carsgen Therapeutics Posts Group Revenue Of RMB125.7 Million For Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2617638376","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617638376?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:15","pubTimestamp":1772802903,"startTime":"0","endTime":"0","summary":"BRIEF-Carsgen Therapeutics Posts Group Revenue Of RMB125.7 Million For YearMarch 6 (Reuters) - CARsgen Therapeutics Holdings Ltd 2171.HK:GROUP'S REVENUE RMB125.7 MILLION FOR YEARFY NET LOSS RMB103 MILLIONFurther company coverage: 2171.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nFWN3ZU0SV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02171","BK1574","BK1585","BK1587"],"gpt_icon":0},{"id":"1193422949","title":"CARsgen-B (02171) Announces 2025 Annual Results and Proposes Amendments to Articles of Association","url":"https://stock-news.laohu8.com/highlight/detail?id=1193422949","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193422949?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:47","pubTimestamp":1772801278,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics Holdings Limited (“CARsgen Therapeutics” or “CARsgen-B (02171)”) announced audited consolidated annual results for the year ended December 31, 2025. According to the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"gpt_icon":0},{"id":"1127125397","title":"CARSGEN-B Reports 2025 Financial Results: Shareholder Loss Narrows Significantly","url":"https://stock-news.laohu8.com/highlight/detail?id=1127125397","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127125397?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:12","pubTimestamp":1772799138,"startTime":"0","endTime":"0","summary":"CARSGEN-B (02171) announced its annual results for the period ending December 31, 2025. The company recorded revenue of RMB 126 million, representing a year-on-year increase of 218.7%. The loss...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171","BK1585","BK1161","BK1574","BK1587"],"gpt_icon":0},{"id":"2617687841","title":"CARsgen posts FY2025 net loss of CNY103 million, down 87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617687841","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617687841?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:04","pubTimestamp":1772798697,"startTime":"0","endTime":"0","summary":"CARsgen reported FY 2025 revenue of CNY 125.7 million, mainly from zevor-cel, and FY 2025 gross profit of about CNY 80 million. The company posted a FY 2025 net loss of about CNY 103 million, down about 87% YoY. Cash and cash equivalents were about CNY 1.1 billion as of Dec. 31, 2025, and CARsgen said cash and cash equivalents at the end of 2026 are expected to be not less than CNY 1.0 billion. For 2025 commercialization, CARsgen said it received 218 confirmed zevor-cel orders from partner Huadong Medicine, and noted zevor-cel was included in China’s Commercial Health Insurance Innovative Drug Catalogue  in December 2025. On the pipeline, the company said China’s regulator accepted the NDA for satri-cel and granted Priority Review; CARsgen expects satri-cel to be approved in H1 2026 and initiate commercialization. CARsgen also highlighted progress in allogeneic CAR-T development and its lentiviral-based in vivo CAR T-cell CARvivo platform, and disclosed a Feb. 12, 2026 strategic cooper","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL11T47r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","BK0187","BK0132","BK0196","BK0175","BK1161","BK1585","BK0188","BK1574","LU2328871848.SGD","000963","02171","BK0183","BK1587","BK0209"],"gpt_icon":0},{"id":"2617369687","title":"CARsgen Therapeutics Holdings Ltd - Expects Cash and Cash Equivalents of at Least RMB1,000 Mln at End of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2617369687","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617369687?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:04","pubTimestamp":1772798657,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nTUA3ZBQ2D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1585","BK1161","02171","BK1587"],"gpt_icon":0},{"id":"2617876356","title":"Press Release: CARsgen Therapeutics Announces 2025 Annual Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2617876356","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617876356?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:04","pubTimestamp":1772798640,"startTime":"0","endTime":"0","summary":"SHANGHAI, March 6, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited , a company focused on developing innovative CAR T-cell therapies, has announced its 2025 Annual Results.-- Cash and cash equivalents were around RMB1,123 million as of December 31,2025. Cash and cash equivalents at the end of 2026 are expected to be not. less than RMB1,000 million. The net loss for the year ended December 31,2025 was RMB103 million, representing a decrease of approximately 87%. compared to the year ended December 31, 2024. In light of operational. factors such as the changes in operating cash flow, we expect to have. -- During 2025, CARsgen has received a total of 218 confirmed orders of. zevor-cel from its commercialization partner Huadong Medicine. In. December 2025, zevor-cel has been included in China's Commercial Health. -- The Center for Drug Evaluation  of the National Medical Products.  and granted Priority Review for satri-cel. The results of satri-cel. confirmatory Phase II trial i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK0187","BK4099","TM","CDE","R","BK4232","BK1574","BK0196","BK4195","03160","LU2328871848.SGD","BK4230","BK4211","BK0188","BK4539","LU1223083913.SGD","BK4007","BK0183","LU1223082196.USD","BK0175","BK4097","LENZ","BK4585","OS","PFS","BK4022","BK4555","BK4139","BK4017","BK1585","BK0209","02171","BK4604","CAR","BK1161","000963","BK1587","LU1969619763.USD","BK0132","LU1223082519.USD"],"gpt_icon":0},{"id":"2617682056","title":"CARsgen Therapeutics -  Group's Revenue RMB125.7 Mln for Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2617682056","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617682056?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:01","pubTimestamp":1772798503,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nFWN3ZU0SV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","02171","BK1585","BK1587","BK1161"],"gpt_icon":0},{"id":"1189877268","title":"CARSGEN-B (02171) Announces Monthly Equity Movements for February 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1189877268","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189877268?lang=en_us&edition=fundamental","pubTime":"2026-03-05 18:43","pubTimestamp":1772707406,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics Holdings Limited reported that its authorized share capital remained at 200.00 billion ordinary shares with a par value of USD 0.00000025 each, totaling USD 50,000. As of the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"gpt_icon":0},{"id":"1134666300","title":"CARsGen-B Shares Extend Decline Amid TCE Data Impact on Autologous CAR-T Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1134666300","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134666300?lang=en_us&edition=fundamental","pubTime":"2026-03-02 11:40","pubTimestamp":1772422846,"startTime":"0","endTime":"0","summary":"CARsGen-B (02171) fell more than 8% in Hong Kong trading, extending recent losses. At the time of writing, the stock was down 8.06% to HK$13, with a turnover of HK$18.93 million. A research report...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","02171","BK1585","BK4588","BK1574","BK4230","VT","BK1161","BK4022","CAR","VXUS","BK1587"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.carsgen.com","stockEarnings":[{"period":"1week","weight":0.4223},{"period":"1month","weight":0.0972},{"period":"3month","weight":-0.009},{"period":"6month","weight":-0.2481},{"period":"1year","weight":0.1802},{"period":"ytd","weight":0.0411}],"compareEarnings":[{"period":"1week","weight":-0.0113},{"period":"1month","weight":-0.066},{"period":"3month","weight":-0.0197},{"period":"6month","weight":-0.035},{"period":"1year","weight":0.0854},{"period":"ytd","weight":-0.0064}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"CARsgen Therapeutics Holdings Ltd is an investment holding company primarily engaged in discovering, researching and developing cell therapies. The Company’s main business is developing chimeric antigen receptor T cell (CAR T) -cell therapies to address clinical needs including but not limited to hematologic malignancies solid tumors and autoimmune diseases. The Company’s main products include zevor-cel (zevorcabtagene autoleucel), satricabtagene autoleucel and allogeneic CAR T-cell products. The Company mainly operates its businesses in China and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.07858},{"month":2,"riseRate":0.6,"avgChangeRate":0.230493},{"month":3,"riseRate":0.2,"avgChangeRate":-0.083853},{"month":4,"riseRate":0.25,"avgChangeRate":-0.092431},{"month":5,"riseRate":0.75,"avgChangeRate":0.085205},{"month":6,"riseRate":0.5,"avgChangeRate":0.033426},{"month":7,"riseRate":0.4,"avgChangeRate":-0.015336},{"month":8,"riseRate":0.6,"avgChangeRate":0.066197},{"month":9,"riseRate":0.4,"avgChangeRate":0.033481},{"month":10,"riseRate":0.6,"avgChangeRate":0.024843},{"month":11,"riseRate":0.6,"avgChangeRate":0.051023},{"month":12,"riseRate":0.4,"avgChangeRate":-0.058482}],"exchange":"SEHK","name":"CARSGEN-B","nameEN":"CARSGEN-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CARSGEN-B(02171),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CARSGEN-B(02171) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CARSGEN-B,02171,CARSGEN-B股票,CARSGEN-B股票老虎,CARSGEN-B股票老虎国际,CARSGEN-B行情,CARSGEN-B股票行情,CARSGEN-B股价,CARSGEN-B股市,CARSGEN-B股票价格,CARSGEN-B股票交易,CARSGEN-B股票购买,CARSGEN-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CARSGEN-B(02171),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CARSGEN-B(02171) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}